Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study.
Primary Outcome Measures:
1. Recurrent venous thromboembolism [ Time Frame: 6 months ]
Primary efficacy outcome: objectively confirmed recurrent VTE occurring during the study period, that means the composite of:
· proximal DVT of the lower limbs (symptomatic or unsuspected), DVT of the upper limb (symptomatic), PE (symptomatic or unsuspected)
Can be done from home
KeywordsApixaban, Dalteparin, Pulmonary embolism
Principal InvestigatorMartina C Murphy, M.D.
Sponsoring GroupDepartment of Medicine
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.